COVID-19 has illustrated the impact of a pandemic and the need for better testing.
Infectious disease outbreaks will occur again in our lifetime. LexaGene’s open-access instrument can be rapidly configured to detect novel pathogens for use in preventing a pandemic by containing the spread quickly after a new pathogen emerges.
LexaGene’s MiQLab™ open-access diagnostic analyzer is ideally suited for preventing such a catastrophe, whether it is caused by influenza, coronavirus, or any other pathogen. In the event of another pandemic, the best way to minimize deaths is to quickly place infected individuals into quarantine. However, such decisions are more easily made if rapid and accurate diagnostics are available at the point-of-need to conclusively determine whether quarantine is required.
Fortunately, facilities with LexaGene’s open-access MiQLab technology in place will be able to accurately detect not only common pathogens but also a novel pathogen within a week of its genome being sequenced. This is because LexaGene’s technology uses standard liquid reagents (20X qPCR) that can be quickly generated by numerous manufacturers and shipped overnight. These manufacturers can generate sufficient reagents to provide worldwide coverage within a weeks’ time.
This speed is in stark contrast to competitor point-of-care technologies that have reagents pre-embedded into complex and expensive cartridges that are only manufactured by a single production site— making it impossible to rapidly meet a rise in demand. The lack of technologies like LexaGene’s puts us at risk of leaving our physicians and nurses without the diagnostic tests required to make critical point-of-care decisions regarding quarantine.
LexaGene’s MiQLab analyzer will rapidly return results to improve quarantine decision making and help minimize the spread of disease that could lead to a pandemic.
(MiQLab is our commercial system; LX Analyzer refers to our beta technology.)